HCAT - Health Catalyst, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.14
+0.09 (+0.33%)
At close: 4:00PM EDT

27.00 -0.14 (-0.52%)
After hours: 5:27PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close27.05
Open27.04
Bid27.13 x 800
Ask27.21 x 800
Day's Range26.35 - 27.46
52 Week Range17.48 - 49.85
Volume581,445
Avg. Volume882,172
Market Cap1.032B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-28.31
Earnings DateMay 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.90
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Health Catalyst Inc (HCAT) Q1 2020 Earnings Call Transcript
    Motley Fool

    Health Catalyst Inc (HCAT) Q1 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Health Catalyst, Inc. first-quarter 2020 earnings conference call. Good afternoon, and welcome to Health Catalyst's earnings conference call for the first quarter of 2020, which ended on March 31, 2020. My name is Adam Brown.

  • GlobeNewswire

    Health Catalyst Reports First Quarter 2020 Results

    SALT LAKE CITY, May 12, 2020 -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today.

  • GlobeNewswire

    Mark Templeton Appointed to Health Catalyst Board of Directors

    Mr. Templeton was appointed to fill an upcoming vacancy after Promod Haque’s current term expires at Health Catalyst’s 2020 annual meeting of its stockholders on June 12, 2020. Mr. Templeton will serve until Health Catalyst’s 2022 annual meeting of its stockholders.

  • The Zacks Analyst Blog Highlights: LOGI, GO, GFL, HCAT and VIE
    Zacks

    The Zacks Analyst Blog Highlights: LOGI, GO, GFL, HCAT and VIE

    The Zacks Analyst Blog Highlights: LOGI, GO, GFL, HCAT and VIE

  • Should You Buy Health Catalyst (HCAT) Ahead of Earnings?
    Zacks

    Should You Buy Health Catalyst (HCAT) Ahead of Earnings?

    Health Catalyst (HCAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Were Hedge Funds Right About Health Catalyst, Inc (HCAT)?
    Insider Monkey

    Were Hedge Funds Right About Health Catalyst, Inc (HCAT)?

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • GlobeNewswire

    Health Catalyst to Announce First Quarter 2020 Operating Results and Host Conference Call on Tuesday, May 12, 2020

    SALT LAKE CITY, April 28, 2020 -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

  • Health Catalyst National Data Repository Helps Clients Battle COVID-19
    PR Newswire

    Health Catalyst National Data Repository Helps Clients Battle COVID-19

    Healthcare providers and public health authorities across the country are struggling to answer complex questions related to the COVID-19 pandemic. Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT) is analyzing the data in its Touchstone™ platform of 80 million de-identified patient records to produce real-world COVID-19 insights related to surveillance, testing, capacity planning, and treatment response—and making the results of that analysis available to customers, health systems, public health authorities, state and local government, and biopharma working on vaccine and therapeutics development.

  • Health Catalyst and Carle Health Partner to Improve Patient Care with Data and Analytics Solutions
    PR Newswire

    Health Catalyst and Carle Health Partner to Improve Patient Care with Data and Analytics Solutions

    Carle Health today joined Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, in announcing a five year, multi-million dollar strategic partnership to improve the quality of patient care, lower costs and meet the changing needs of patients, providers and payors in today's rapidly evolving healthcare marketplace.

  • GlobeNewswire

    Health Catalyst, Inc. Prices Upsized Offering of $200 Million 2.50% Convertible Senior Notes Due 2025

    Health Catalyst, Inc. (HCAT) (the “Company” or “Health Catalyst”) announced today the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering of $175.0 million aggregate principal amount of notes. In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $30.0 million aggregate principal amount of notes.

  • GlobeNewswire

    Health Catalyst, Inc. Announces Proposed Offering of $175 Million Convertible Senior Notes

    Health Catalyst, Inc. (HCAT) (the “Company” or “Health Catalyst”) announced today that it intends to offer, subject to market conditions and other factors, $175.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company expects to grant the initial purchasers an option to purchase up to an additional $26.25 million aggregate principal amount of notes. The Company intends to use a portion of the net proceeds from the offering of notes to pay the cost of the capped call transactions described below and approximately $57.0 million of the net proceeds to repay in full and terminate its term loan facility.

  • Health Catalyst Launches Four Additional COVID-19 Solutions and a Modular Bundle
    PR Newswire

    Health Catalyst Launches Four Additional COVID-19 Solutions and a Modular Bundle

    Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced meaningful developments in its initial COVID-19 solutions and is launching the following: a COVID-19 Registry, Dashboard, and Capacity Planning Tool, with a new set of Financial Impact Planning Resources in development. The technology associated with all of these solutions is offered to Health Catalyst clients at no cost, with the Capacity Planning Tool also available to any healthcare organization, free of charge.

  • Why Health Catalyst (HCAT) Stock Might be a Great Pick
    Zacks

    Why Health Catalyst (HCAT) Stock Might be a Great Pick

    Health Catalyst (HCAT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Health Catalyst Expands COVID-19 Response Support and Provides Infrastructure to Enable Readiness for Future Demands
    PR Newswire

    Health Catalyst Expands COVID-19 Response Support and Provides Infrastructure to Enable Readiness for Future Demands

    Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that multiple client sites are already using its new COVID-19 Solutions announced last week, well ahead of the anticipated March 31 launch. Additionally, a growing number of its health system clients are using the company's agile, adaptable, open Data Operating System's (DOS) ingestion, warehousing, analytics and services capabilities to meet evolving COVID-19-driven demands. More capabilities and solution refinements are surfacing and becoming available, including public health surveillance reporting for seven states and longer-term infrastructure planning for the anticipated next wave of COVID-19 and other novel viruses, with this future readiness enabled by DOS.

  • Health Catalyst Plans to Support Health System Clients' COVID-19 Response with Three Initial Solutions Focused on Patient Tracking, Public Health Surveillance and Staff Augmentation Support
    PR Newswire

    Health Catalyst Plans to Support Health System Clients' COVID-19 Response with Three Initial Solutions Focused on Patient Tracking, Public Health Surveillance and Staff Augmentation Support

    Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that, after dozens of conversations with health system clients, the company will initially be offering three COVID-19 Solutions to its domestic clients, with the first of these solutions becoming available to pilot clients by the end of March. The technology associated with these solutions will be offered to all clients at no incremental cost through the end of 2020. In the days and weeks ahead, Health Catalyst will continue to explore with clients additional potential analytics solutions helpful in addressing the COVID-19 situation.

  • GlobeNewswire

    Health Catalyst Reports Fourth Quarter and Year End 2019 Results

    SALT LAKE CITY, Feb. 27, 2020 -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today.

  • J.P. Morgan: 2 “Strong Buy” Healthcare Stocks With Over 50% Upside
    TipRanks

    J.P. Morgan: 2 “Strong Buy” Healthcare Stocks With Over 50% Upside

    Digitization of the world we live in has disrupted the healthcare industry, giving rise to the healthcare information technology (IT) segment of the market. The emergence of this space and the technology it offers has transformed the way healthcare providers and organizations care for patients. Not to mention efficiency has improved dramatically. Demand for these digital solutions isn’t expected to slow anytime soon, with Grand View Research predicting that the digital healthcare market will expand at a CAGR of 27%, reaching $509.2 billion by 2025.Bearing this in mind, investing firm J.P. Morgan took a look at several healthcare IT names ahead of their upcoming fourth quarter earnings releases.“Sentiment on the group has been largely favorable, with the group up 12% since Q3 earnings in November vs the remaining Healthcare Technology & Distribution group up 14% and the SPX 8%-plus,” analyst Anne Samuel commented.In the report, the firm highlights two tickers in particular that it believes can not only deliver solid prints, but also reward investors through 2020 and beyond. After using TipRanks’ Stock Screener tool, we found out each boasts a “Strong Buy” consensus rating from the Street, and has a substantial upside potential from the current share price. We’re talking more than 50% here.Health Catalyst Inc. (HCAT)With its cloud-based data platform, Health Catalyst offers data and analytics solutions to healthcare organizations. As the company gears up for its February 27 earnings release, J.P. Morgan has high hopes.The investment banking firm's analyst, Anne Samuel, notes that she will be focused on how many new Data Operating System (DOS) clients were added during the year as well as dollar-based retention. Additionally, Samuel highlights the fact that the company thinks the Medicity conversion opportunity is approaching an inflection point in 2020 given that this past summer, cross-sell conversations kicked off.Based on Samuel’s estimates, the analyst expects net new customers for 2019 to land at 14, which would reflect 28% year-over-year customer growth. In terms of 2020 guidance, she is forecasting 18 net new DOS subscription customers and 7% same-store growth, amounting to 25% DOS subscription revenue growth. However, thanks to Medicity drag, the total revenue gain is expected to come in at 22%. As a result, this brings the 2020 revenue prediction to $186 million, which falls in line with the consensus.While Samuel does point out that HCAT operates in a highly competitive environment and that there could be an expense shift of $200,00 from Q3 into Q4, her bullish thesis remains very much intact. “We see significant white space in an $8 billion TAM, with over 20% revenue growth driven by mid-teens annual customer wins. We estimate the company reaches EBTIDA profitability in the next four years as a maturing customer base drives incremental leverage. The model is predictable with over 90% recurring revenue, 107% net dollar-based retention, and a sticky customer base, never having lost an all-access customer,” the analyst explained.Taking all of this into consideration, Samuel maintained both her Overweight call and $50 price target. Should this target be met, shares could be in for a twelve-month gain of 66%. (To watch Samuel’s track record, click here)Overall, it has been relatively quiet when it comes to other analyst activity. In the last three months, only 3 analysts have issued ratings. However, as they were all Buys, the word on the Street is that HCAT is a Strong Buy. Based on the $48.33 average price target, shares could climb 60% higher in the next twelve months. (See Health Catalyst stock analysis on TipRanks)Livongo Health Inc. (LVGO)Moving on to the firm’s next pick, we come across Livongo Health. For patients battling chronic health conditions, its digital health platform makes it easy to access personalized digital guidance and health coaching through a smart connected device. While the healthcare name has experienced significant volatility, the firm remains optimistic.Ahead of its Q4 earnings release on March 2, Samuel, who also covers this stock, wrote that LVGO already “blessed Street numbers on its Q3 call for $276 million equating to 63% year-over-year growth.” She added, “Looking at the economic value added (EVA) that they reported in Q3, a 40% conversion rate on $208 million year-to-date EVA would equate to a 70% revenue growth run rate on our math.”When the results are announced, Samuel anticipates that the Street will be paying close attention to 2020 guidance and the sustainability of rapid growth, noting that management stated 2020 will be an “investment year”. On top of this, the analyst is hoping for an update on enrollment, pipeline for new growth and any changes in the competitive landscape.In terms of the fourth quarter figures, Samuel is calling for revenue of $49.4 million and an EBITDA loss of $5.5 million, both of which would land within the guided range. For 2020, the analyst expects the company to guide for $281 million in revenue, a 66% increase if achieved, gross profit margins of 72% and a fiscal 2020 EBITDA loss of $25 million.Despite the EBITDA figure being in the red, Samuel believes LVGO will be able to reach operating income profitability in 2021. Additionally, the analyst argued, “The company is minimally penetrated in a vast and growing chronic disease market, as more than half of the U.S. population has one or more chronic conditions and an additional 4,000 Americans are diagnosed with diabetes each day. LVGO’s rapid growth profile is attractive, and unique in Healthcare IT with our model calling for an 85% revenue CAGR over the next 3 years as the company increases its member base.”In line with her optimistic take, Samuel kept an Overweight rating and price target of $43 on the stock. This target conveys her confidence in LVGO’s ability to climb 55% higher in the next twelve months.What does the rest of the Street think about LVGO? As it turns out, other analysts are on the same page. With 100% Street support, the message is clear: the stock is a Strong Buy. Not to mention the $45.67 average price target implies 64% upside potential. (See Livongo stock analysis on TipRanks)

  • GlobeNewswire

    Health Catalyst to Participate in Upcoming Investor Conference

    SALT LAKE CITY, Feb. 24, 2020 -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

  • GlobeNewswire

    Health Catalyst Announces Agreement to Acquire Able Health, a Leading SaaS Provider of Quality and Regulatory Measurement Tracking and Reporting

    Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that it has entered into a definitive agreement to acquire Able Health, Inc. (“Able Health”), a San Francisco-based company that is a leading SaaS provider of quality and regulatory measurement tracking and reporting to healthcare providers and risk-bearing entities. The Able Health SaaS application will strengthen Health Catalyst’s existing Quality and Regulatory Measures capabilities.

  • GlobeNewswire

    Health Catalyst to Announce Fourth Quarter and Full Year 2019 Operating Results and Host Conference Call on Thursday, February 27, 2020

    SALT LAKE CITY, Feb. 14, 2020 -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

  • Health Catalyst Joins the Partnership on AI
    PR Newswire

    Health Catalyst Joins the Partnership on AI

    Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced its membership in the Partnership on AI (PAI) as its first ever healthcare member.

  • Is Health Catalyst, Inc. (NASDAQ:HCAT) Worth US$37.0 Based On Its Intrinsic Value?
    Simply Wall St.

    Is Health Catalyst, Inc. (NASDAQ:HCAT) Worth US$37.0 Based On Its Intrinsic Value?

    Does the January share price for Health Catalyst, Inc. (NASDAQ:HCAT) reflect what it's really worth? Today, we will...

  • WakeMed Health & Hospitals Selects Health Catalyst to Transform Healthcare Delivery through Centralized Data and Analytics
    PR Newswire

    WakeMed Health & Hospitals Selects Health Catalyst to Transform Healthcare Delivery through Centralized Data and Analytics

    Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that WakeMed Health & Hospitals (WakeMed) will implement Health Catalyst's Data Operating System (DOS™) and Rapid Response Analytics (RRA) solution which will assist WakeMed in providing efficient, quality care across the Raleigh, N.C.-based health system.

  • GlobeNewswire

    Health Catalyst to Participate in Upcoming J.P. Morgan Healthcare Conference

    SALT LAKE CITY, Dec. 30, 2019 -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

  • Hedge Funds Welcomed Health Catalyst, Inc (HCAT) With Open Arms
    Insider Monkey

    Hedge Funds Welcomed Health Catalyst, Inc (HCAT) With Open Arms

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]